The Risk of Developing Hepatocellular Carcinoma Persists in Chronic Hepatitis B Patients Even After the Long-Term...

Nucleos(t)ide analogs (NUCs) are used in the treatment of chronic hepatitis B (CHB). It is still uncertain whether the risk of incident hepatocellular carcinoma (HCC) continues beyond 5 or 10 years after the initiation of NUC treatment. We aimed to elucidate this in CHB patients receiving long-term NUC treatment.

This was a multicenter, observational study that included patients who began NUC treatment between July 2000 and March 2019; patients were retrospectively enrolled up to March 2019 and followed up until August 2024.

Among 737 CHB patients (156 with cirrhosis) who started NUC treatment, 147 developed HCC during a median follow-up period of 144.2 months. The 5-, 10-, and 15-year cumulative HCC rates were 11.2%, 18.4%, and 23.1%, respectively. Independent risk factors for subsequent HCC occurrence included older age, male sex, cirrhosis, low platelet count, low ALT levels, and high γ-GTP levels at NUC initiation. After 5 years, the risk factors were cirrhosis, high γ-GTP levels, and high AFP levels, whereas after 10 years, they were cirrhosis and diabetes. Landmark analysis revealed that the 5-year cumulative HCC incidence was 8.1% at 5 years and 5.8% at 10 years after NUC initiation. In noncirrhotic patients, cumulative HCC incidence at 5 years was 5.8%, whereas 5-year cumulative incidences starting at 5 and 10 years were 4.1% and 4.8%, respectively, remaining stable over time.

The risk of HCC persists long after NUC initiation. In noncirrhotic patients, the risk remains stable more than 10 years after NUC treatment initiation.